Premium
Antierythrocyte autoantibody formation after therapy with interleukin‐2 and gamma‐interferon
Author(s) -
Perez Raymond,
Padavic Kristin,
Krigel Robert,
Weiner Louis
Publication year - 1991
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19910515)67:10<2512::aid-cncr2820671021>3.0.co;2-5
Subject(s) - medicine , autoantibody , renal cell carcinoma , autoimmunity , immunology , interferon gamma , immune system , interleukin 2 , immunotherapy , interferon , pathology , antibody
Abstract The cardiovascular, renal, pulmonary, and dermatologic toxicities of interleukin‐2 (IL‐2) and gamma‐interferon (IFN) are well described. However, autoimmune toxicities have only recently been noticed. The authors report the development of warm autoantibodies against erythrocytes in a patient receiving IL‐2 (3.75 × 10 6 cetus units/m 2 intravenous bolus three times per week) and gamma‐IFN (0.1 mg/m 2 subcutaneously three times per week) for metastatic renal cell carcinoma. Other potential causes of autoantibody formation, such as drugs, infection, and collagen vascular disease, were excluded. Both gamma‐IFN and IL‐2 have the potential to trigger or exacerbate autoimmunity due to either aberrant expression of restricted antigens or inhibition of normal cellular immune suppressor mechanisms.